Buscar
Imunon Inc
IMNNAñadir a la lista de seguimiento
1.590USD
-0.010-0.63%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
6.24MCap. mercado
PérdidaP/E TTM
Más Datos de Imunon Inc Compañía
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Información de Imunon Inc
Símbolo de cotizaciónIMNN
Nombre de la empresaImunon Inc
Fecha de salida a bolsaOct 27, 1993
Director ejecutivoLindborg (Stacy R)
Número de empleados25
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 27
Dirección997 Lenox Dr Ste 100
CiudadLAWRENCEVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal08648
Teléfono16098969100
Sitio Webhttps://imunon.com/
Símbolo de cotizaciónIMNN
Fecha de salida a bolsaOct 27, 1993
Director ejecutivoLindborg (Stacy R)
Ejecutivos de Imunon Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
76.72K
+3.30%
Mr. Michael H. Tardugno
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
64.40K
+6.85%
Mr. James E. Dentzer
Mr. James E. Dentzer
Independent Director
Independent Director
14.96K
+74.50%
Mr. Frederick J. (Fred) Fritz
Mr. Frederick J. (Fred) Fritz
Independent Director
Independent Director
14.10K
+73.28%
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Independent Director
9.32K
+53.77%
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
7.11K
+78.16%
Dr. Khursheed Anwer, Ph.D.
Dr. Khursheed Anwer, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
3.65K
--
Ms. Susan Eylward
Ms. Susan Eylward
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
2.90K
--
Dr. Douglas Vincent Faller, M.D., Ph.D.
Dr. Douglas Vincent Faller, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kimberly Graper
Ms. Kimberly Graper
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
76.72K
+3.30%
Mr. Michael H. Tardugno
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
64.40K
+6.85%
Mr. James E. Dentzer
Mr. James E. Dentzer
Independent Director
Independent Director
14.96K
+74.50%
Mr. Frederick J. (Fred) Fritz
Mr. Frederick J. (Fred) Fritz
Independent Director
Independent Director
14.10K
+73.28%
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Independent Director
9.32K
+53.77%
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
7.11K
+78.16%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Imunon Inc?
Los cinco principales accionistas de Imunon Inc son: Dr. Stacy R. Lindborg, Ph.D.
¿Cuántas instituciones poseen acciones de Imunon Inc (IMNN)?
A fecha de 2026Q1, 46 instituciones poseen acciones de Imunon Inc, con un valor de mercado combinado de aproximadamente 431.10K, lo que representa el 10.82% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 47090.00.